ArticleFrontiers in cardiovascular medicine2025
The impact of inflammatory factors on patients with concurrent lung cancer and acute pulmonary embolism.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is a leading cause of cancer-related mortality globally, with acute pulmonary embolism (APE) significantly worsening the prognosis of affected patients. Inflammatory pathways are increasingly recognized for their dual role in both oncogenesis and thrombotic events. This study aimed to investigate the prognostic significance of specific inflammatory biomarkers, particularly neutrophil-mediated mechanisms, in lung cancer patients complicated by APE. Methods: A retrospective cohort analysis was conducted on 90 lung cancer patients admitted to the Second Xiangya Hospital of Central South University between January 2019 and December 2022. Propensity score matching (PSM) was employed to ensure balanced demographic and clinical covariates. Multivariate logistic regression analyses were performed to identify independent predictors of APE occurrence and disease severity. Results: Multivariate logistic regression identified elevated neutrophil count as an independent predictor of APE occurrence (adjusted OR = 3.068, 95% CI: 1.472-6.394, Discussion: Our findings highlight neutrophilia as a potential biomarker for APE susceptibility in lung cancer patients. Furthermore, elevated uric acid levels and a diminished PLR may serve as valuable indicators of disease severity in this high-risk population. The study underscores the critical need to integrate these inflammatory markers into standardized clinical risk assessment frameworks to optimize therapeutic strategies and improve patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.